Appendix HStudies with poor internal validity

Publication Details

Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum. 2010 Jun;39(6):425–441. [PubMed: 20223500]
Carmona L, Descalzo MA, Perez-Pampin E, et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis. 2007 Jul;66(7):880–885. [PMC free article: PMC1955107] [PubMed: 17324968]
Dretzke J, Edlin R, Round J, et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-alpha) inhibitors, adalimumab and infliximab, for Crohn’s disease. Health Technol Assess. 2011 Feb;15(6):1–244. [PubMed: 21291629]
Feagan BG, Reilly MC, Gerlier L, Brabant Y, Brown M, Schreiber S. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn’s disease in the PRECiSE 2 study. Aliment Pharmacol Ther. 2010 Jun;31(12):1276–1285. [PubMed: 20298497]
Gerloni V, Pontikaki I, Gattinara M, et al. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum. 2005 Feb;52(2):548–553. [PubMed: 15693004]
Huang ML, Ran ZH, Shen J, Li XB, Xu XT, Xiao SD. Efficacy and safety of adalimumab in Crohn’s disease: meta-analysis of placebo-controlled trials. J Dig Dis. 2011 Jun;12(3):165–172. [PubMed: 21615869]
Langley RG, Strober BE, Gu Y, Rozzo SJ, Okun MM. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. Br J Dermatol. 2010 Jun;162(6):1349–1358. [PubMed: 20394634]
Lovell DJ, Giannini EH, Reiff A, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 2003 Jan;48(1):218–226. [PubMed: 12528122]
Menter A, Reich K, Gottlieb AB, et al. Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations. J Drugs Dermatol. 2008 Dec;7(12):1137–1146. [PubMed: 19137767]
Nikfar S, Ehteshami-Afshar S, Abdollahi M. A systematic review and meta-analysis of the efficacy and adverse events of infliximab in comparison to corticosteroids and placebo in active ulcerative colitis. International Journal of Pharmacology Vol. 72011:325–332.
Schreiber S, Lawrance IC, Thomsen OO, Hanauer SB, Bloomfield R, Sandborn WJ. Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther. 2011 Jan;33(2):185–193. [PubMed: 21083671]
Seong SS, Choi CB, Woo JH, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol. 2007 Apr;34(4):706–711. [PubMed: 17309133]
Shao LM, Chen MY, Cai JT. Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn’s disease. Aliment Pharmacol Ther. 2009 Mar 15;29(6):605–614. [PubMed: 19183161]
Smith LS, Nelson M, Dolder CR. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn’s disease. Ann Pharmacother. 2010;44:333–342. 2010/02/02 ed. [PubMed: 20118143]
Volkmann ER, Agrawal H, Maranian P, Furst DE. Rituximab for rheumatoid arthritis: A meta-analysis and systematic review. Clinical Medicine Insights: Therapeutics. 2010;2:749–760.
Wolfe F, Caplan L, Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scandinavian Journal of Rheumatology. 2007;36(3):172–178. [PubMed: 17657669]
Wilson DC, Thomas AG, Croft NM, et al. Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease. Journal of pediatric gastroenterology and nutrition. 2010;50(SUPPL 1):S14–34.
Fleischmann RM, Baumgartner SW, Tindall EA, et al. Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol. 2003 Apr;30(4):691–696. [PubMed: 12672185]
Bathon JM, Fleischmann RM, Van der Heijde D, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol. 2006 Feb;33(2):234–243. [PubMed: 16465653]
Bejarano V, Quinn M, Conaghan PG, et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum. 2008 Oct 15;59(10):1467–1474. [PubMed: 18821658]
Kristensen LE, Jakobsen AK, Bartels EM, et al. The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials. Scand J Rheumatol. 2011;40:1–7. 2010/10/19 ed. [PubMed: 20950126]
Moreland LW, Weinblatt ME, Keystone EC, et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol. 2006 May;33(5):854–861. [PubMed: 16541481]
Reich K, Sinclair R, Roberts G, Griffiths CE, Tabberer M, Barker J. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis. Curr Med Res Opin. 2008 May;24(5):1237–1254. [PubMed: 18355421]
Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007 Jul 19;357(3):228–238. [PubMed: 17634458]
Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007 Jul 19;357(3):239–250. [PubMed: 17634459]
Venkateshan SP, Sidhu S, Malhotra S, Pandhi P. Efficacy of biologicals in the treatment of rheumatoid arthritis. a meta-analysis. Pharmacology. 2009;83(1):1–9. [PubMed: 18957873]